The Forgotten Ones: Why Children Remain on the Periphery of Medical Crises

The ongoing Ebola outbreak in the Democratic Republic of Congo has claimed over 3,000 lives since May, with children under five bearing the brunt of the tragedy. These statistics are disturbing, but they highlight a more insidious issue – one that echoes through every medical crisis and threatens to undermine global efforts to combat infectious diseases.

The crux of the problem lies in the lack of treatment options for children. Adult patients can be treated with experimental antiviral drugs like remdesivir, but their younger counterparts are often excluded from these trials due to concerns over dosage and side effects. The EBO-PEP study currently underway in the Congo exemplifies this paradox – by leaving out children weighing under 30 kilograms, researchers may inadvertently perpetuate a cycle of neglect.

The absence of pediatric-specific treatments is not merely a matter of expediency; it’s rooted in the fundamental biology of childhood. Children metabolize medications differently than adults, and their smaller bodies require specialized formulations to avoid adverse reactions. This knowledge has been well-documented for decades, yet research institutions and pharmaceutical companies continue to prioritize adult-focused studies.

Treating children during outbreaks is often a logistical nightmare – even when life-saving treatments exist. As Doctors Without Borders points out, this is due in part to the limited availability of pediatric-specific data and the lack of tailored knowledge. The case of an American doctor treated at Berlin’s Charité hospital in May serves as a poignant reminder of this reality. While his family was given an experimental antibody treatment to prevent infection, the uncertainty created by limited available data and a lack of pediatric-specific knowledge made it difficult.

This problem is not new. In 2020, the Global Accelerator for Pediatric Formulations network was established to accelerate child-friendly medicine development worldwide – a testament to the persistent gap in our understanding of pediatric pharmacology. The 2024 mpox epidemic in the Congo only serves to underscore this issue: despite a vaccine being available, children were disproportionately affected due to the lack of tailored treatments.

The responsibility for perpetuating this imbalance lies not solely with researchers or pharmaceutical companies; funders and regulators also share blame. As Marc Biot so eloquently puts it – “it is faster and cheaper if you only focus on adults.” Yet, we’re left asking: at what cost? The lives of children caught in the crossfire of medical crises are but one example.

To prioritize child-centric research without compromising treatment development speed and efficacy, pediatric-specific trials should be incorporated into the earliest stages of drug development. This would not only ensure that treatments are tailored to meet children’s unique needs but also provide valuable insights for adult patients.

It is imperative that we reorient our priorities, acknowledging the critical importance of child-centric treatments in outbreak scenarios. We must rethink our approach to medical research, particularly when it comes to treating vulnerable populations like children and pregnant women. Only then can we hope to mitigate the devastating impact of medical crises on these most defenseless among us.

As the Congo’s Ebola outbreak continues to claim lives, one sobering truth remains: until we prioritize the needs of children in medical research, we risk condemning them – and ourselves – to a future marred by neglect and tragedy.